Literature DB >> 12230423

Thrombolysis for acute stroke in routine clinical practice.

Dawn M Bravata1, Nancy Kim, John Concato, Harlan M Krumholz, Lawrence M Brass.   

Abstract

BACKGROUND: Studies have demonstrated that thrombolytic therapy for acute stroke can be given safely and effectively in study settings with experienced clinicians, but the patient outcomes associated with thrombolytic therapy in routine clinical practice require investigation.
OBJECTIVES: To compare outcomes among patients given intravenous thrombolysis in routine clinical practice with the results of the National Institute of Neurological Disorders and Stroke rt-PA Study (NINDS cohort) and to examine whether protocol deviations are associated with adverse events.
METHODS: Retrospective cohort of community-based patients given thrombolysis for acute stroke from May 1, 1996, through December 31, 1998, in 16 Connecticut hospitals (Connecticut cohort).
RESULTS: Forty-two (67%) of 63 patients in the Connecticut cohort had at least 1 major protocol deviation, and 61 (97%) had major or minor protocol deviations. Overall, the in-hospital mortality was higher in the Connecticut cohort (16/63 [25%]) compared with the NINDS cohort (40/312 [13%]; P =.01). The serious extracranial hemorrhage rate was also higher for the Connecticut cohort (8/63 [13%] vs 5/312 [2%]; P =.001). Patients in the Connecticut cohort without major protocol deviations had outcomes similar to those in the NINDS cohort; however, patients in the Connecticut cohort with major protocol deviations had higher rates of in-hospital mortality (13/42 [31%] vs 40/312 [13%]; P =.002) and serious extracranial hemorrhage (7/42 [17%] vs 5/312 [2%]; P =.001).
CONCLUSIONS: Protocol deviations occur commonly when thrombolytic therapy is given to stroke patients in routine clinical practice. Patients who receive thrombolysis with major protocol deviations have higher rates of in-hospital mortality and serious extracranial hemorrhage than patients in the NINDS cohort.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230423     DOI: 10.1001/archinte.162.17.1994

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  Use of bone morphogenetic proteins in spinal fusion surgery for older adults with lumbar stenosis: trends, complications, repeat surgery, and charges.

Authors:  Richard A Deyo; Alex Ching; Laura Matsen; Brook I Martin; William Kreuter; Jeffrey G Jarvik; Heather Angier; Sohail K Mirza
Journal:  Spine (Phila Pa 1976)       Date:  2012-02-01       Impact factor: 3.468

2.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

Review 3.  Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice.

Authors:  Dawn M Bravata
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Implementation Strategies for Telestroke: A Qualitative Study of Telestroke Networks in North Carolina.

Authors:  Christopher M Shea; Kea Turner; Amir Alishahi Tabriz; Steve North
Journal:  Telemed J E Health       Date:  2018-09-07       Impact factor: 3.536

5.  Telestroke Adoption Among Community Hospitals in North Carolina: A Cross-Sectional Study.

Authors:  Christopher M Shea; Amir Alishahi Tabriz; Kea Turner; Steve North; Kristin L Reiter
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-05-18       Impact factor: 2.136

6.  Spinal Epidural Hematoma as a Complication of Intravenous Thrombolysis in an Acute Ischemic Stroke Patient.

Authors:  Ron Liebkind; Jukka Putaala; Mika Leppä; Jukka Oula; Turgut Tatlisumak
Journal:  Case Rep Neurol       Date:  2010-04-27

Review 7.  Stroke, dementia, and drug delivery.

Authors:  G A Ford; C A Bryant; A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 8.  Development of regional programs to speed treatment of stroke.

Authors:  Jeffrey A Switzer; David C Hess
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

9.  Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Authors:  Eric E Adelman; Phillip A Scott; Lesli E Skolarus; Allison K Fox; Shirley M Frederiksen; William J Meurer
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-26       Impact factor: 2.136

10.  Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.